Nephrocare Health Services Limited Share Price & Stock Analysis

Nephrocare Health Services Limited (NSE: NEPHROPLUS, BSE: 544647) is a Hyderabad, Telangana-based company in the Specialty Care Clinics industry. With a market capitalisation of ₹6,339 Cr, it ranks #758 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹650.00 (as of 16 Nov 2026), the share price is 16.8% below its 52-week high of ₹781.50 and 45.7% above its 52-week low of ₹446.00.

Key Metrics

Current Price₹650.00
Market Cap₹6,339 Cr
NSE SymbolNEPHROPLUS
BSE Code544647
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Services > Specialty Care Clinics
P/E Ratio76.7
Return on Equity6.88%
Return on Assets7.03%
52-Week Range₹446.00 – ₹781.50
3-Month Price Change-3.7%
Beta (1Y)0.48
HeadquartersHyderabad, Telangana
Websitewww.nephroplus.com

Latest Quarterly Results — Q2 FY27

Revenue₹303 Cr
Net Profit₹34 Cr
Net Margin11.1%
EPS (Basic)₹3.34
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Nephrocare Health Services Limited Quarterly Revenue and Profit Trend

Nephrocare Health Services Limited reported revenue of ₹303 Cr in Q2 FY27, up 7.7% from ₹282 Cr in Q1 FY27. It posted a net profit of ₹34 Cr for the quarter, against a net profit of ₹32 Cr in Q1 FY27 (up 4.9%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹260 Cr (Q3 FY26) to ₹303 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹303 Cr₹34 Cr11.1%
Q1 FY27₹282 Cr₹32 Cr11.3%
Q4 FY26₹266 Cr₹30 Cr11.4%
Q3 FY26₹260 Cr₹32 Cr12.4%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 58.31% of Nephrocare Health Services Limited's shares as of Sept 2026, against 63.85% in Dec 2025 (−5.54 percentage points). Delivery averaged 48.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Nephrocare Health Services Limited

Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.

Products and Services

1. Providing Dialysis and Related Healthcare Services-This segment operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Providing Dialysis and Related Healthcare Services-100%

Frequently Asked Questions

What is the current share price of Nephrocare Health Services Limited?

Nephrocare Health Services Limited is trading at ₹650.00, with a market capitalisation of ₹6,339 Cr.

Which sector does Nephrocare Health Services Limited belong to?

Nephrocare Health Services Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Specialty Care Clinics).

What are the key financial ratios of Nephrocare Health Services Limited?

Nephrocare Health Services Limited has a P/E of 76.7 and a return on equity of 6.88%.

What is the stock symbol of Nephrocare Health Services Limited?

Nephrocare Health Services Limited is listed on the NSE under the symbol NEPHROPLUS and on the BSE under the scrip code 544647.

What were Nephrocare Health Services Limited's latest quarterly results?

In Q2 FY27, Nephrocare Health Services Limited reported revenue of ₹303 Cr and net profit of ₹34 Cr, with basic EPS of ₹3.34 (consolidated, parsed from the company's exchange filing).

What is the promoter holding in Nephrocare Health Services Limited?

Promoters held 58.31% of Nephrocare Health Services Limited's shares as of Sept 2026, against 63.85% in Dec 2025 (−5.54 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.